Literature DB >> 23582637

The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals.

Martina Trunschke1, Dominik Conrad, Sven Enterlein, Judith Olejnik, Kristina Brauburger, Elke Mühlberger.   

Abstract

The Ebola virus (EBOV) RNA-dependent RNA polymerase (RdRp) complex consists of the catalytic subunit of the polymerase, L, and its cofactor VP35. Using immunofluorescence analysis and coimmunoprecipitation assays, we mapped the VP35 binding site on L. A core binding domain spanning amino acids 280-370 of L was sufficient to mediate weak interaction with VP35, while the entire N-terminus up to amino acid 380 was required for strong VP35-L binding. Interestingly, the VP35 binding site overlaps with an N-terminal L homo-oligomerization domain in a non-competitive manner. N-terminal L deletion mutants containing the VP35 binding site were able to efficiently block EBOV replication and transcription in a minigenome system suggesting the VP35 binding site on L as a potential target for the development of antivirals.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23582637      PMCID: PMC3773471          DOI: 10.1016/j.virol.2013.03.013

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  54 in total

1.  Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture.

Authors:  Gabriele Neumann; Heinz Feldmann; Shinji Watanabe; Igor Lukashevich; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Complexes of Sendai virus NP-P and P-L proteins are required for defective interfering particle genome replication in vitro.

Authors:  S M Horikami; J Curran; D Kolakofsky; S A Moyer
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

3.  Homo-oligomerization of Marburgvirus VP35 is essential for its function in replication and transcription.

Authors:  Peggy Möller; Nonia Pariente; Hans-Dieter Klenk; Stephan Becker
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR.

Authors:  Zongdi Feng; Melissa Cerveny; Zhipeng Yan; Bin He
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

5.  Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein.

Authors:  St Patrick Reid; Washington B Cárdenas; Christopher F Basler
Journal:  Virology       Date:  2005-08-10       Impact factor: 3.616

6.  RNA polymerase I-driven minigenome system for Ebola viruses.

Authors:  Allison Groseth; Heinz Feldmann; Steven Theriault; Gülsah Mehmetoglu; Ramon Flick
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  Human parainfluenza virus type 2 L protein regions required for interaction with other viral proteins and mRNA capping.

Authors:  Machiko Nishio; Masato Tsurudome; Dominique Garcin; Hiroshi Komada; Morihiro Ito; Philippe Le Mercier; Tetsuya Nosaka; Daniel Kolakofsky
Journal:  J Virol       Date:  2010-11-10       Impact factor: 5.103

8.  Role of Ebola virus VP30 in transcription reinitiation.

Authors:  Miguel J Martínez; Nadine Biedenkopf; Valentina Volchkova; Bettina Hartlieb; Nathalie Alazard-Dany; Olivier Reynard; Stephan Becker; Viktor Volchkov
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

9.  Phosphorylation of VP30 impairs ebola virus transcription.

Authors:  Jens Modrof; Elke Mühlberger; Hans-Dieter Klenk; Stephan Becker
Journal:  J Biol Chem       Date:  2002-06-06       Impact factor: 5.157

10.  The respiratory syncytial virus polymerase has multiple RNA synthesis activities at the promoter.

Authors:  Sarah L Noton; Laure R Deflubé; Chadene Z Tremaglio; Rachel Fearns
Journal:  PLoS Pathog       Date:  2012-10-18       Impact factor: 6.823

View more
  33 in total

1.  Ebolavirus polymerase uses an unconventional genome replication mechanism.

Authors:  Laure R Deflubé; Tessa N Cressey; Adam J Hume; Judith Olejnik; Elaine Haddock; Friederike Feldmann; Hideki Ebihara; Rachel Fearns; Elke Mühlberger
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-08       Impact factor: 11.205

2.  An RNA polymerase II-driven Ebola virus minigenome system as an advanced tool for antiviral drug screening.

Authors:  Emily V Nelson; Jennifer R Pacheco; Adam J Hume; Tessa N Cressey; Laure R Deflubé; John B Ruedas; John H Connor; Hideki Ebihara; Elke Mühlberger
Journal:  Antiviral Res       Date:  2017-08-12       Impact factor: 5.970

3.  Analysis of the highly diverse gene borders in Ebola virus reveals a distinct mechanism of transcriptional regulation.

Authors:  Kristina Brauburger; Yannik Boehmann; Yoshimi Tsuda; Thomas Hoenen; Judith Olejnik; Michael Schümann; Hideki Ebihara; Elke Mühlberger
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

4.  An Intrinsically Disordered Peptide from Ebola Virus VP35 Controls Viral RNA Synthesis by Modulating Nucleoprotein-RNA Interactions.

Authors:  Daisy W Leung; Dominika Borek; Priya Luthra; Jennifer M Binning; Manu Anantpadma; Gai Liu; Ian B Harvey; Zhaoming Su; Ariel Endlich-Frazier; Juanli Pan; Reed S Shabman; Wah Chiu; Robert A Davey; Zbyszek Otwinowski; Christopher F Basler; Gaya K Amarasinghe
Journal:  Cell Rep       Date:  2015-04-09       Impact factor: 9.423

5.  HSP90 Chaperoning in Addition to Phosphoprotein Required for Folding but Not for Supporting Enzymatic Activities of Measles and Nipah Virus L Polymerases.

Authors:  Louis-Marie Bloyet; Jérémy Welsch; François Enchery; Cyrille Mathieu; Sylvain de Breyne; Branka Horvat; Boyan Grigorov; Denis Gerlier
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

6.  Conserved peptide vaccine candidates containing multiple Ebola nucleoprotein epitopes display interactions with diverse HLA molecules.

Authors:  Sahil Jain; Manoj Baranwal
Journal:  Med Microbiol Immunol       Date:  2019-02-21       Impact factor: 3.402

7.  Assembly of the Ebola Virus Nucleoprotein from a Chaperoned VP35 Complex.

Authors:  Robert N Kirchdoerfer; Dafna M Abelson; Sheng Li; Malcolm R Wood; Erica Ollmann Saphire
Journal:  Cell Rep       Date:  2015-06-25       Impact factor: 9.423

Review 8.  Epidemiology and Management of the 2013-16 West African Ebola Outbreak.

Authors:  M L Boisen; J N Hartnett; A Goba; M A Vandi; D S Grant; J S Schieffelin; R F Garry; L M Branco
Journal:  Annu Rev Virol       Date:  2016-08-15       Impact factor: 10.431

9.  Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome.

Authors:  Priya Luthra; Parameshwaran Ramanan; Chad E Mire; Carla Weisend; Yoshimi Tsuda; Benjamin Yen; Gai Liu; Daisy W Leung; Thomas W Geisbert; Hideki Ebihara; Gaya K Amarasinghe; Christopher F Basler
Journal:  Cell Host Microbe       Date:  2013-07-17       Impact factor: 21.023

10.  Dynamic Phosphorylation of VP30 Is Essential for Ebola Virus Life Cycle.

Authors:  Nadine Biedenkopf; Clemens Lier; Stephan Becker
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.